Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat.
about
Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4.Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative diseaseDevelopment of allosteric modulators of GPCRs for treatment of CNS disordersThe external globus pallidus: progress and perspectivesDevelopment and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.Metabotropic glutamate receptor 4 in the basal ganglia of parkinsonian monkeys: ultrastructural localization and electrophysiological effects of activation in the striatopallidal complex.Microtubule: a common target for parkin and Parkinson's disease toxins.Glutamate receptors as therapeutic targets for Parkinson's disease.Metabotropic glutamate receptors: physiology, pharmacology, and disease.mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease.Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.Therapeutic potential of targeting glutamate receptors in Parkinson's disease.Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indicationsGroup III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential.Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's diseaseElectrophysiological and behavioral effects of group III metabotropic glutamate receptors on pallidal neurons in normal and parkinsonian rats.In silico studies targeting G-protein coupled receptors for drug research against Parkinson's disease.
P2860
Q24647634-B10224F6-7EA3-461A-82AD-6A16B2F895DEQ26995351-A82199E5-4B18-4FB8-89DA-33655914D001Q34373958-4502008E-184C-4535-8C61-378C58FB6930Q34512150-4A86094C-3372-42DD-9850-606F15348051Q34534818-257861C0-9136-4F2C-977E-88BF65ADB0A7Q35589979-4566B0E0-0EA4-44C8-BDCA-1EF97412B59DQ36203237-DB5B57AC-1331-40AE-957D-7D0C11D03AE7Q36374309-05CB3EC0-E594-418F-9113-DA98E1244638Q36641831-7C6951C6-098C-4E9F-8922-7DD9FF7EAEF5Q37585401-A255D664-2707-4AE9-82BD-C7A98DB83D42Q37670222-44A3742D-7952-4522-B570-D12612031349Q37693720-CBA20725-F4AC-4F53-B6D4-C8DB05B1ACFBQ37782115-9D2B52AD-1283-4604-89AB-1DA27D08871DQ37999106-0FB6826F-1996-48D4-B475-E9EA5F2B045BQ38031832-0663BDFE-2BC2-4FD5-81DD-83F9A3329000Q38056852-0EE26AC1-AC41-4A1D-822E-8CB125B9D31AQ38092819-72F63283-5633-4CCA-A7E0-0E4783C455F9Q38190016-382EACF6-306C-44DA-8B23-25F539C224DBQ38209092-FF322210-81FB-40F8-801E-BAC0F238F6D2Q38242117-50B94CD6-F5A8-4B2C-B1A7-897CA61A6CC7Q39265062-1C3CAEBB-902C-4C2E-B4F6-FCD49A14253BQ39282544-2C059F4A-CE07-4864-B0F7-5D77C4503B6CQ46771144-5D1BBD80-0AA6-44AA-A908-304177CED5BEQ52665081-30D9C3EB-AC65-4D08-9EDE-7CA8BD6AAF88
P2860
Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Activation of group III metabo ...... in the reserpine-treated rat.
@en
Activation of group III metabo ...... in the reserpine-treated rat.
@nl
type
label
Activation of group III metabo ...... in the reserpine-treated rat.
@en
Activation of group III metabo ...... in the reserpine-treated rat.
@nl
prefLabel
Activation of group III metabo ...... in the reserpine-treated rat.
@en
Activation of group III metabo ...... in the reserpine-treated rat.
@nl
P2860
P356
P1476
Activation of group III metabo ...... a in the reserpine-treated rat
@en
P2093
Marcus J Messenger
Nicholas MacInnes
P2860
P356
10.1038/SJ.BJP.0705566
P407
P50
P577
2003-11-03T00:00:00Z